# CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immunisation reviews</td>
<td>3</td>
</tr>
<tr>
<td>Immunisation policy and practice</td>
<td>5</td>
</tr>
<tr>
<td>Australian Childhood Immunisation Register and immunisation coverage</td>
<td>10</td>
</tr>
<tr>
<td>Adverse events following immunisation</td>
<td>13</td>
</tr>
<tr>
<td>Social research</td>
<td>18</td>
</tr>
<tr>
<td>Indigenous health</td>
<td>24</td>
</tr>
<tr>
<td>Research and surveillance of vaccine preventable diseases</td>
<td>27</td>
</tr>
<tr>
<td>General surveillance reports</td>
<td>27</td>
</tr>
<tr>
<td>Haemophilus influenzae type b</td>
<td>29</td>
</tr>
<tr>
<td>Hepatitis A and B</td>
<td>30</td>
</tr>
<tr>
<td>Human papillomavirus</td>
<td>31</td>
</tr>
<tr>
<td>Influenza</td>
<td>33</td>
</tr>
<tr>
<td>Measles</td>
<td>41</td>
</tr>
<tr>
<td>Meningococcal disease</td>
<td>43</td>
</tr>
<tr>
<td>Mumps</td>
<td>45</td>
</tr>
<tr>
<td>Pertussis</td>
<td>45</td>
</tr>
<tr>
<td>Pneumococcal disease</td>
<td>50</td>
</tr>
<tr>
<td>Poliomyelitis</td>
<td>53</td>
</tr>
<tr>
<td>Rotavirus</td>
<td>54</td>
</tr>
<tr>
<td>Rubella</td>
<td>55</td>
</tr>
<tr>
<td>Varicella-zoster</td>
<td>56</td>
</tr>
<tr>
<td>Other vaccine preventable and infectious diseases</td>
<td>59</td>
</tr>
<tr>
<td>Hajj and mass gatherings</td>
<td>65</td>
</tr>
<tr>
<td>Health economics</td>
<td>69</td>
</tr>
<tr>
<td>Vaccine trials</td>
<td>71</td>
</tr>
<tr>
<td>Refugee health</td>
<td>74</td>
</tr>
</tbody>
</table>

Current at 25 October 2017

A complete list of NCIRS publications (1997–2017) is available on the NCIRS website at [www.ncirs.edu.au](http://www.ncirs.edu.au)
Underline reads: Immunisation reviews


**Brotherton JM.** Festschrift for Professor Margaret Burgess AO. *Communicable Diseases Intelligence* 2004;28:349-55.
Immunisation reviews, continued


Immunisation policy and practice


Immunisation policy and practice, continued


**Immunisation policy and practice, continued**


Immunisation policy and practice, continued


Immunisation policy and practice, continued


Burgess MA, McIntyre PB. Vaccines and the cold chain: is it too hot...or too cold? [editorial]. *Medical Journal of Australia* 1999;171:82.


Australian Childhood Immunisation Register and immunisation coverage


Australian Childhood Immunisation Register and immunisation coverage, continued


Hull BP, McIntyre PB. Compliance with three simultaneous vaccinations due at the one visit at 12 months of age in Australia. Communicable Diseases Intelligence 2007;31:198-202.


Hull BP, Lawrence GL, MacIntyre CR, McIntyre PB. Is low immunisation coverage in inner urban areas of Australia due to low uptake or poor notification? Australian Family Physician 2003;32:1041-3.

Australian Childhood Immunisation Register and immunisation coverage, continued

Torvaldsen S, Hull BP, McIntyre PB. Using the Australian Childhood Immunisation Register to track the transition from whole-cell to acellular pertussis vaccines. Communicable Diseases Intelligence 2002;26:581-3.


Hull BP, McIntyre PB. A re-evaluation of immunisation coverage estimates from the Australian Childhood Immunisation Register. Communicable Diseases Intelligence 2000;24:161-4.


Adverse events following immunisation

Cashman P, Macartney K, Khandaker G, King C, Gold M, Durrheim DN. Participant-centred active surveillance of adverse events following immunisation: a narrative review. *International Health* 2017;9:164-76.


Adverse events following immunisation, continued


Adverse events following immunisation, continued


Mahajan D, Menzies R, Roomiani I, Lawrence G. Supplementary report: surveillance of adverse events following immunisation among children aged less than seven years in Australia, 1 January to 30 June 2009. *Communicable Diseases Intelligence* 2010;34:49-53.


Adverse events following immunisation, continued


Lawrence GL, Aratchige PE, Hill R. Supplementary report: surveillance of adverse events following immunisation among children aged less than 7 years in Australia, 1 January to 30 June 2007. *Communicable Diseases Intelligence* 2007;31:379-82.


Adverse events following immunisation, continued


Lawrence GL, Burgess MA, Kass RB. Age-related risk of adverse events following yellow fever vaccination in Australia. *Communicable Diseases Intelligence* 2004;28:244-8.


Social research


King C, Leask J. The impact of a vaccine scare on parental views, trust and information needs: a qualitative study in Sydney, Australia. *BMC Public Health* 2017;17:106.


Corben P, Leask J. To close the childhood immunization gap, we need a richer understanding of parents' decision-making. *Human Vaccines and Immunotherapeutics* 2016;12:3168-76.


Social research, continued


Social research, continued


Leask J, Chapman S, Cooper Robbins SC. "All manner of ills": the features of serious diseases attributed to vaccination. *Vaccine* 2010;28:3066-70.


Social research, continued


Social research, continued


McIntyre P, Wood N. Does universal hepatitis B vaccination at birth have a negative impact on breastfeeding? *Australian Midwifery: Journal of the Australian College of Midwives* 2004;17:4-5.


Social research, continued


Indigenous health


Indigenous health, continued


Indigenous health, continued

Hull BP, McIntyre PB. What do we know about 7vPCV coverage in Aboriginal and Torres Strait Islander children? Communicable Diseases Intelligence 2004;28:238-43.


Research and surveillance of vaccine preventable diseases

**General surveillance reports**


Research and surveillance of vaccine preventable diseases, continued

General surveillance reports, continued


Research and surveillance of vaccine preventable diseases, continued

General surveillance reports, continued

Haemophilus influenzae type b


Research and surveillance of vaccine preventable diseases, continued

**Haemophilus influenzae type b, continued**


**Hepatitis A and B**


Research and surveillance of vaccine preventable diseases, continued

**Hepatitis A and B, continued**


**Human papillomavirus**

Research and surveillance of vaccine preventable diseases, continued

**Human papillomavirus, continued**


Gold MS, McIntyre P. Human papillomavirus vaccine safety in Australia: experience to date and issues for surveillance. *Sexual Health* 2010;7:320-4.
Research and surveillance of vaccine preventable diseases, continued

**Human papillomavirus, continued**


**Influenza**


Research and surveillance of vaccine preventable diseases, continued

**Influenza, continued**

Cheng AC, Macartney KK, Waterer GW, Kotsimbos T, Kelly PM, Blyth CC. Repeated vaccination does not appear to impact upon influenza vaccine effectiveness against hospitalization with confirmed influenza. *Clinical Infectious Diseases* 2017;64:1564-72.


Research and surveillance of vaccine preventable diseases, continued

**Influenza, continued**


Research and surveillance of vaccine preventable diseases, continued

**Influenza, continued**


Research and surveillance of vaccine preventable diseases, continued

Influenza, continued


Research and surveillance of vaccine preventable diseases, continued

Influenza, continued


Research and surveillance of vaccine preventable diseases, continued

**Influenza, continued**


Seppelt IM, Webb SA, Booy R. All health professionals should receive the 2009 H1N1 influenza vaccine [editorial]. *Critical Care and Resuscitation* 2010;12:3-5.


Research and surveillance of vaccine preventable diseases, continued

Influenza, continued


Seale H, Corbett S, Dwyer DE, MacIntyre CR. Feasibility exercise to evaluate the use of particulate respirators by emergency department staff during the 2007 influenza season. *Infection Control and Hospital Epidemiology* 2009;30:710-2.


Newall AT, Wood JG, MacIntyre CR. Influenza-related hospitalisation and death in Australians aged 50 years and older. *Vaccine* 2008;26:2135-41.


Research and surveillance of vaccine preventable diseases, continued

**Influenza, continued**


**Measles**


Research and surveillance of vaccine preventable diseases, continued

**Measles, continued**


Research and surveillance of vaccine preventable diseases, continued

**Measles, continued**


**Meningococcal disease**


Research and surveillance of vaccine preventable diseases, continued

**Meningococcal disease, continued**


Research and surveillance of vaccine preventable diseases, continued

Meningococcal disease, continued


Booy R. Risk and protective factors for meningococcal disease in adolescents [letter]. Archives of Disease in Childhood 2006;July:Online.


Mumps


Pertussis


Research and surveillance of vaccine preventable diseases, continued

Pertussis, continued


Research and surveillance of vaccine preventable diseases, continued

**Pertussis, continued**


McIntyre PB, Sintchenko V. The "how" of polymerase chain reaction testing for *Bordetella pertussis* depends on the "why". *Clinical Infectious Diseases* 2013;56:332-4.

Research and surveillance of vaccine preventable diseases, continued

**Pertussis, continued**


Research and surveillance of vaccine preventable diseases, continued

Pertussis, continued


Research and surveillance of vaccine preventable diseases, continued

Pertussis, continued


Pneumococcal disease


Tashani M, Rashid H, Mulholland K, Booy R. Carrier priming to improve pneumococcal disease control and reduce the international program’s cost in children [commentary]. *Pneumonia* 2016;8:16.
Research and surveillance of vaccine preventable diseases, continued

**Pneumococcal disease, continued**


Research and surveillance of vaccine preventable diseases, continued

**Pneumococcal disease, continued**


Research and surveillance of vaccine preventable diseases, continued

**Pneumococcal disease, continued**


**Poliomyelitis**

Research and surveillance of vaccine preventable diseases, continued

**Poliomyelitis, continued**

Macartney K. Heads up: Monovalent polio vaccines are better. *Journal of Paediatrics and Child Health* 2010;46:275.


**Rotavirus**


Research and surveillance of vaccine preventable diseases, continued

Rotavirus, continued


Rubella


Research and surveillance of vaccine preventable diseases, continued

Rubella, continued


Gidding HF, Young M, Pugh R, Burgess M. Rubella in Australia: can we explain two recent cases of congenital rubella syndrome? Communicable Diseases Intelligence 2003;27:537-40.


Varicella-zoster

Sheel M, Beard FH, Dey A, Macartney K, McIntyre PB. Rates of hospitalisation for herpes zoster may warrant vaccinating Indigenous Australians under 70. Medical Journal of Australia In press.


Research and surveillance of vaccine preventable diseases, continued

**Varicella-zoster, continued**


Research and surveillance of vaccine preventable diseases, continued

Varicella-zoster, continued


MacIntyre CR, Chu CP, Burgess MA. Use of hospitalization and pharmaceutical prescribing data to compare the prevaccination burden of varicella and herpes zoster in Australia. *Epidemiology and Infection* 2003;131:675-82.


Research and surveillance of vaccine preventable diseases, continued

Varicella-zoster, continued


Other vaccine preventable and infectious diseases


Research and surveillance of vaccine preventable diseases, continued

Other vaccine preventable and infectious diseases, continued


Research and surveillance of vaccine preventable diseases, continued

Other vaccine preventable and infectious diseases, continued


Research and surveillance of vaccine preventable diseases, continued

Other vaccine preventable and infectious diseases, continued


Research and surveillance of vaccine preventable diseases, continued

Other vaccine preventable and infectious diseases, continued


Research and surveillance of vaccine preventable diseases, continued

Other vaccine preventable and infectious diseases, continued

Cheuvart B, Burgess M, Zepp F, Mertsola J, Wolter J, Schuerman L. Anti-diphtheria antibody seroprotection rates are similar 10 years after vaccination with dTpa or DTPa using a mathematical model. Vaccine 2004;23:336-42.


Hajj and mass gatherings


Hajj and mass gatherings, continued


Hajj and mass gatherings, continued


Ridda I, King C, Rashid H. Pneumococcal infections at Hajj: current knowledge gaps. *Infectious Disorders – Drug Targets* 2014;14:177-84.


**Hajj and mass gatherings, continued**


Health economics


Beutels P, Scuffham PA, MacIntyre CR. Funding of drugs: do vaccines warrant a different approach? The Lancet Infectious Diseases 2008;8:727-33.


Health economics, continued


Vaccine trials


Vaccine trials, continued


Booy R, Van der Meeren O, Ng SP, Celzo F, Ramakrishnan G, Jacquet JM. A decennial booster dose of reduced antigen content diphtheria, tetanus, acellular pertussis vaccine (Boostrix™) is immunogenic and well tolerated in adults. Vaccine 2010;29:45-50.


Marshall H, McIntyre P, Robertson D, Dinan L, Hardt K. Primary and booster immunization with a diphtheria, tetanus, acellular pertussis, hepatitis B (DTPa-HBV) and Haemophilus influenzae type b (Hib) vaccine administered separately or together is safe and immunogenic. International Journal of Infectious Diseases 2010;14:e41-e9.


Vaccine trials, continued


McIntyre PB, Turnbull FM, Egan AM, Burgess MA, Wolter JM, Schuerman LM. High levels of antibody in adults three years after vaccination with a reduced antigen content diphtheria-tetanus-acellular pertussis vaccine. *Vaccine* 2004;23:380-5.


Refugee health


Sheikh M, MacIntyre CR. The impact of intensive health promotion to a targeted refugee population on utilisation of a new refugee paediatric clinic at The Children's Hospital at Westmead. *Ethnicity and Health* 2009;14:393-405.


